Immunic (IMUX) announced the appointment of Michael Panzara as chief medical officer, effective April 24. Panzara will lead the company’s development organization, including clinical development, medical affairs, and regulatory affairs, and will be a partner to the CEO and the board of directors in defining and driving the overall company strategy. Panzara succeeds Andreas Muehler. Panzara most recently served as chief medical officer of Neurvati Neurosciences.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX: